Here is the design of a clinical trial:

Official Title: Effects of Super-Bolus on Postprandial Glycemia After High Glycemic Index Meal in Children With Type 1 Diabetes Mellitus- Randomized Study

Included conditions:
- Diabetes Mellitus, Type 1

Study Armgroups:
- {'label': 'Normal Bolus', 'type': 'ACTIVE_COMPARATOR', 'description': 'Pre-breakfast insulin will be given as a Normal Bolus 15 minutes before the high-glycemic index meal (cornflakes and milk). The Normal Bolus will be calculated based on individual insulin-to-carbohydrate ratio (ICR).', 'interventionNames': ['Drug: Insulin Glulisine', 'Drug: Insulin Aspart', 'Drug: Insulin Lispro']}
- {'label': 'Super Bolus', 'type': 'EXPERIMENTAL', 'description': 'Pre-breakfast insulin will be given as a Super Bolus 15 minutes before the high-glycemic index meal (cornflakes and milk). The Super Bolus will be calculated based on individual ICR increased to 150% and basal insulin will be suspended for 2 hours at the same time.', 'interventionNames': ['Drug: Insulin Glulisine', 'Drug: Insulin Aspart', 'Drug: Insulin Lispro']}

Interventions:
- {'type': 'DRUG', 'name': 'Insulin Glulisine', 'description': 'A type of bolus insulin will be insulin glulisine if participant used insulin glulisine before entering the trial.', 'armGroupLabels': ['Normal Bolus', 'Super Bolus'], 'otherNames': ['Apidra']}
- {'type': 'DRUG', 'name': 'Insulin Aspart', 'description': 'A type of bolus insulin will be insulin aspart if participant used insulin aspart before entering the trial.', 'armGroupLabels': ['Normal Bolus', 'Super Bolus'], 'otherNames': ['NovoRapid']}
- {'type': 'DRUG', 'name': 'Insulin Lispro', 'description': 'A type of bolus insulin will be insulin lispro if participant used insulin lispro before entering the trial.', 'armGroupLabels': ['Normal Bolus', 'Super Bolus'], 'otherNames': ['Humalog, Liprolog']}

Primary Outcomes:
- {'measure': 'Postprandial Glycemia', 'description': 'Postprandial blood glucose excursion measured by self monitoring of blood glucose (SMBG)', 'timeFrame': '90 minutes after the prandial bolus'}

Please estimate the sample size based on the assumption: 
Significance level (α) = 0.05, power = 80%, withdrawal rate = 20%, correlation = 0.
Sample size
        The sample size was estimated based on the calculations performed using the StatsDirect statistical software (V.3.1.4, StatsDirect, Chesire, UK). A total of 72 participants will be required to show a difference of 30 mg/dl (1.7 mmol//l) and an SD of 41 (which corresponds to the standard deviation of the paired differences being 82) and standard deviations for observations within treatment being 58 at the 90th minute of the study (the primary endpoint), with Î± = 0.05 and 80% powerâassuming a 20% withdrawal rate. The correlation was set to 0 (conservative approach). We assume that glycemia differences between the study groups mentioned above are significant for metabolic control.